Ritalin (methylphenidate)

Ritalin is one of the most recognized pharmaceutical products globally, primarily used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy. It was first synthesized in 1944 by chemist Leandro Panizzon, who named the drug after his wife, Rita. The brand has since become a cornerstone of neuropharmacology.

Today, Ritalin is manufactured across many global sites to meet international demand, including major facilities in the United States, Europe, and Asia. Despite the expiration of its original patents, which has allowed for numerous generic versions to enter the market, the Ritalin brand name remains a core intellectual property of the original developer's successor.

Ownership of the brand resides with Novartis, a Swiss multinational pharmaceutical corporation. Novartis was formed through the 1996 merger of Ciba-Geigy and Sandoz. The company oversees global distribution and maintains the brand's legacy as a gold standard in its therapeutic category, operating out of its headquarters in Basel, Switzerland.